Since starting our three-year strategy in 2021 we have made valuable progress in advancing our vision of a world without type 1 diabetes.
However, we won’t stop until we have improved the lives of everyone affected by type 1 and developed cures for the condition.
Download our latest Impact Report
Goal 1: Drive research to cure, treat and prevent type 1 diabetes
We have funded several exciting research projects including:
- Our new Small Grants Awards have funded three projects currently underway in laboratories around the country led by researchers in the early stages of their career.
- Our Connect Immune Research programme, in partnership with Versus Arthritis, the MS Society, the British Society for Immunology, Alopecia UK, the Psoriasis and Psoriatic Arthritis Alliance (PAPAA), Coeliac UK and Bowel Research UK, is exploring commonalities between different autoimmune conditions.
Find out more about our research progress, download our Impact Report.
Goal 2: Accelerate access to type 1 treatment technologies and medicines
- Our long-term advocacy and research around hybrid closed loop artificial pancreas technology resulted in an NHS England pilot that should benefit 1,000 people with type 1 diabetes.
- We delivered three workshops as part of our Research to Reality project, which will accelerate the availability of emerging treatments and technology.
- Our Covid and Beyond report provided insights into the mental and physical health of people with type 1 and the disruption of care during the pandemic.
- Alongside Diabetes UK, our campaign for better access to glucose monitoring systems on the NHS has helped boost access from 10% to 47% in England.
Find out more, download our Impact Report.
Goal 3: Support people living with type 1 diabetes
- Our Covid-19 materials were our most-read content in 2021 with over 80% of website visitors being new to the charity, helping us to reach more people during the uncertainty of the pandemic.
- The number of school staff taking our online e-learning module to support pupils with type 1 increased by 175% with more than 30,500 sessions.
- Taking our information and support events online during the pandemic meant we doubled the number of events we held and trebled the number of attendees to 1,053.
- We have developed a plan to address health inequality in type 1, which will be underpinning a range of our work in policy, information and support.
Find out more, download our Impact Report.
Thank you for making it all possible
“My thanks go to our supporters, volunteers, staff and Board who have helped us navigate and deliver with pride and integrity on our mission in 2021” ~ Karen Addington, Chief Executive
With special thanks to Steve and Sally Morgan of The Steve Morgan Foundation
Our Accelerator Programme Philanthropists:
- Dominic Christian and Kate Birch
- Lincoln Benet
- Niall Curran and Sue Reid
- Rosemary, Gordon and Cameron Fuller
- The Haywood Family
- Wilson Leech
- The Manktelow Family
- The Rt. Hon. Theresa May
- The Pardoe Family
Companies:
- Abbott Diabetes Care UK
- Dexcom UK Distribution Ltd
- Insulet International Ltd
- Roche Diabetes Care UK
- Lilly UK
- Novo Nordisk Ltd
- Sanofi UK
- Air Liquide Healthcare Ltd
- Medtronic Ltd
- Medtrum Ltd
- Menarini Diagnostics Ltd
- Dextro Energy GmbH
- The Syncona Foundation
- Next PLC
- Ford Motor Company Ltd
- Peter Cooper Motor Group
- Hoban Waste Management
Trusts:
- The Alan and Babette Sainsbury Charitable Fund
- The Cadogan Charity
- Coldstones Charitable Trust
- The Elizabeth and Prince Zaiger Trust
- Garfield Weston Foundation
- The Hugh Fraser Foundation
- Hummingbird Charitable Trust
- Lloyd’s Charities Trust
- Miss Margaret Butters Reekie Charitable Trust
- The Mercers’ Company
- Nimar Charitable Trust
- The R S Macdonald Charitable Trust
- The Simon Gibson Charitable Trust
- The TJH Foundation
And all our Patrons for their generous investment in our work.
Download the full Impact Report for 2021
